Dupilumab Biosimilar - Research Grade

Human

IL-4R alpha

>1mg/ml

Human IgG4 (S228P/KDel)

Manfidokimab Biosimilar - Research Grade (ICH5256), Rademikibart Biosimilar - Research Grade (ICH5271), Stapokibart Biosimilar - Research Grade (ICH5277), Comekibart Biosimilar - Research Grade (ICH5444), Elarekibep Biosimilar - Research Grade (ICH5511)

https://www.imgt.org/mAb-DB/

ICH3002

P24394

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of dupilumab, supplied for research use only. It is a human IgG4 (S228P hinge-stabilised, C-terminal K-del) monoclonal antibody built around the interleukin-4 receptor alpha chain (IL-4Ralpha), the same target as the originator drug, and is not intended for human or veterinary use. As a bench reagent it is useful as a positive control or reference standard in IL-4Ralpha binding assays, as a blocking tool to interrupt type 2 cytokine signalling in cell-based systems, and as a comparator in biosimilarity, ELISA, SPR/BLI affinity, and epitope-competition workflows. It also supports assay development, antibody-format engineering, and Fc-function studies. Produced recombinantly and offered at research grade with low endotoxin (typically <1 EU/mg, with ultra-low <0.5 EU/mg options) and available in bulk milligram-to-gram quantities, it suits both in-vitro experiments and preclinical characterisation where a consistent, well-defined anti-IL-4Ralpha reagent is required. It is a research analog, not the clinical formulation, and should not be used therapeutically. IL-4Ralpha (encoded by IL4R, UniProt P24394) is the shared, ligand-binding subunit of the receptors for interleukin-4 and interleukin-13, two central drivers of type 2 (allergic) immunity. IL-4Ralpha pairs with the common gamma chain to form the type I receptor (IL-4 only, mainly on haematopoietic cells) and with IL-13Ralpha1 to form the type II receptor (IL-4 and IL-13, on many non-haematopoietic cells). Ligand engagement activates JAK1/JAK3 or JAK1/JAK2/TYK2 and phosphorylates STAT6, driving Th2 differentiation, IgE class switching, eosinophil recruitment, goblet-cell mucus production, and barrier dysfunction. Because IL-4Ralpha is common to both cytokines, blocking it simultaneously dampens IL-4 and IL-13 signalling, which underlies its relevance in atopic and inflammatory disease research.

IL-4 receptor subunit alpha, IL-4R subunit alpha, IL-4RA, Interleukin-4 receptor subunit alpha, IL4R

Detects human IL-4R alpha. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Dupilumab.

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

S228P

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Q: Is the Dupilumab biosimilar available in gram quantities?

A: Yes — it is supplied in scalable milligram to gram quantities for heavy-usage and high-throughput laboratories.

Q: Is this research-grade Dupilumab suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Dupilumab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Dupilumab that binds human IL-4R alpha.